Work

Vaccinating against infiltrative glioma: antigen selection, neuronal niches, and immune access

Year: 2026
Type: article
Abstract: Glioma vaccines seek to direct immunity against malignant cells, including those dispersed beyond the tissue used to identify vaccine antigens. These infiltrative cells occupy neuronal, perivascular and white matter environments, where antigen expression, immune access and treatment sensitivity may differ from those in the tumor mass. In this narrative review, we examine how spatial tumor biology can guide antigen selection, vaccine platform choice, and the evaluation of antitumor immunity. We connect the pathology of diffuse invasion with evidence on neuron–glioma communication, histone mutations and glucose metabolism, tracing the steps from antigen expression to natural presentation and distinguishing systemic immunogenicity from recognition of residual cells. Histone-mutant gliomas illustrate a central difficulty: an oncogenic mutation may form a candidate antigen while shaping the tumor state in which immunity must act, yet evidence for vaccination differs across molecular entities. Studies of glucose transporter 1 similarly highlight the distinct metabolic requirements of malignant cells, myeloid cells, and effector lymphocytes. Against this background, we assess peptide, dendritic cell, nucleic acid, and viral vector approaches, with combinations designed to support immune priming or local effector function. We then propose preclinical and clinical evaluations that relate antigen coverage, presentation, and immune engagement to residual tumor control. The aim is to align vaccine design and evaluation with the biology of the infiltrative disease that remains after treatment.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7236655752
FWCI:
Cites: 102
Cited by:
Related to: 10
Parts: 2